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Identification of mutations that guide therapy selection for patients with cancer is now 21 
routine in many clinical centres. The majority of assays used for solid tumour 22 
profiling use DNA sequencing to interrogate somatic point mutations as they are 23 
relatively easy to identify and interpret. However many cancers, including high-grade 24 
serous ovarian, oesophageal and small cell lung cancer, are driven by somatic 25 
structural variants that are not measured by these assays. Therefore, there is 26 
currently an unmet need for clinical assays that can cheaply and rapidly profile 27 
structural variants in solid tumours. In this review we survey the landscape of 28 
“actionable” structural variants in cancer and identify promising detection strategies 29 
based on massively parallel sequencing. 30 
 31 
 32 
 33 
 34 
 35 
36 
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The necessity for increased profiling of structural variants in the clinic 37 
Sequencing of tumour cohorts has provided key insights into tumour etiology[1,2] 38 
and has facilitated the development of new DNA based biomarkers for use in the 39 
clinic[3]. The current paradigm for biomarker discovery involves comprehensive, 40 
high-cost sequencing (usually exome or whole-genome) across moderately sized 41 
cohorts, then subsequent application of cheaper, targeted sequencing for biomarker 42 
detection in the clinic. This approach has yielded biomarkers that assist with 43 
diagnosis[4,5], prognosis[6,7], personalised therapy selection[8,9] and clinical trial 44 
stratification[10]. These biomarkers are now being internationally accepted into 45 
molecular pathology as shown by a recent landmark consensus whitepaper for 46 
nervous system tumour diagnosis[11] which will be incorporated into the World 47 
Health Organization classification of glioma. 48 
 49 
Comprehensive approaches such as whole-genome (WGS) and whole-exome 50 
(WES) sequencing yield information on somatic point mutations, also known as 51 
single nucleotide variants (SNVs, See Glossary), small somatic insertions/deletions 52 
(INDELs), and somatic structural variants (SVs). These approaches have the benefit 53 
of identifying multiple mutations simultaneously, albeit at increased cost. However, 54 
given the reality that most actionable mutations are SNVs, the majority of clinical 55 
sequencing is currently performed using low-cost targeted gene panels that 56 
interrogate SNVs[12].     57 
 58 
There are, however, many patients that will not benefit from SNV assays as their 59 
cancers are characterised by high numbers of SVs rather than SNVs. Furthermore, 60 
SV driven tumours may have few, if any, SNV drivers, as demonstrated by a recent 61 
large-scale pan-cancer study[13]. Ciriello and colleagues analysis of 3,299 tumours 62 
showed a hyperbolic relationship between the frequencies of SNVs and SVs across 63 
different tumour types, potentially arising from differences in aberrant DNA repair 64 
and mutagen exposure. The clinical implication of this work is that in the majority of 65 
cancers the major driver mutations are either SNV or SV mutations. For common 66 
cancers that are SV driven, such as high-grade serous ovarian[14], oesophageal[15], 67 
neuroblastoma[16], small-cell lung cancer[17], and triple-negative breast 68 
cancers[18], the current bias for implementation of SNV based assays leaves 69 
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clinicians with very limited data for precision medicine. In addition, these tumours are 70 
also enriched for loss of classical tumour suppressor genes including TP53, RB1, 71 
NF1, which are not directly actionable. There is a significant opportunity to extend 72 
clinical options for patients if cheaper methods for structural variant profiling can be 73 
developed for wider implementation, as exemplified by the repurposing of 74 
trastuzumab to treat gastric and other cancers with amplification of ERBB2[19]. 75 
 76 
Current state of the art in the clinic 77 
Traditional cytogenetic techniques such as fluorescence in situ hybridisation (FISH) 78 
have been used clinically to profile SVs in haematological cancers for over 20 79 
years[20].  However, when applied to solid malignancies, these technologies suffer 80 
from a number of drawbacks, the most significant being poor performance when 81 
applied to archival samples and, in contrast to haematological cancer, significant 82 
barriers to their use on disaggregated tumour tissue in vitro culture or from flow 83 
cytometry analyses. Recent European Guidelines for cytogenetic investigations in 84 
tumours have now recommended the use of orthogonal technologies to improve SV 85 
detection[21]. Alternative technologies such as array comparative genomic 86 
hybridization (aCGH) have been used in large-scale clinical trials to select patients 87 
with specific SVs using the OncoCopy[10] and OncoArray[22] platforms. While these 88 
studies show that aCGH is a viable clinical assay, the main weaknesses are a lack of 89 
standardised bioinformatics pipelines[23], high sample costs compared to equivalent 90 
sequencing technologies, an inability to interrogate balanced SVs, and the 91 
requirement for a different workflow in addition to those in place for panel-based 92 
sequencing. We therefore focus the remainder of this review on how newer 93 
sequencing approaches may enable identification of SVs in the clinic.  94 
 95 
Prime suspects for clinical translation 96 
Figure 1 provides an overview of common cancer related structural variation and the 97 
technologies currently available for detection. For detailed descriptions on structural 98 
variant classification and aetiology we direct the reader to recent reviews [24–27]. In 99 
the following section we focus on cancer promoting SVs that provide strong 100 
exemplars for clinical decision making.  101 
 102 
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Oncogenic fusions - Figure 1a 103 
The prototypical oncogenic fusion, BCR-ABL in chronic myeloid leukaemia is the 104 
result of a reciprocal translocation between chromosomes 22 and 9 causing a BCR-105 
ABL fusion protein[28]. Patients with this fusion respond to the tyrosine kinase 106 
inhibitor imatinib, which represents the earliest example of a rationally targeted 107 
cancer therapy[29]. Subsequent studies have uncovered specific fusions across a 108 
range of tumour types[30,31]. These fusions commonly arise either via translocation 109 
(e.g. BCR-ABL[28]), deletion (e.g. TMPRSS2-ERG[32]) or inversion (e.g. EML4-110 
ALK[33]). In cases such as TMPRSS2 and ALK, the single gene may also have 111 
multiple possible fusion partners[32,34]. ALK fusions in non-small cell lung cancer 112 
are now a critical target for therapy. In contrast, intensive study on the TMPRSS2-113 
ERG fusions which are found in up to 50% of prostate cancers[35], has not yet 114 
demonstrated therapeutic or functional insights. At present the majority of identified 115 
fusions in solid tumours have unknown function. These functional challenges mirror 116 
similar problems in identifying driver SNV mutations but it is important to emphasize 117 
that some cancers have specific mutator phenotypes that are selective for oncogenic 118 
fusions. For example, a subset of lung adenocarcinomas have been shown to be 119 
exclusively driven by fusions[36]. Conversely, fusions may also have classical loss of 120 
function effects and a recent study in prostate cancer detected an inversion causing 121 
a fusion of MSH2 and NRXN1, which inactivated MSH2 causing mis-match repair 122 
deficiency[37].  123 
 124 
Clinical assays to identify fusions have focused on detection of known markers. 125 
Break-apart FISH, where probes located at either side of the breakpoint show a 126 
separation in the presence of the fusion, has been the assay of choice for clinical 127 
profiling. Where fusion specific antibodies exist, IHC has been applied as a simple 128 
low-cost alternative. Alternative approaches using sequencing based methods will 129 
depend highly on the recurrent nature of the underlying genomic aberration and the 130 
intron size of the two fused genes. If the aberration involves a loss of genetic 131 
material, then the detection task is easier as the absence of exons in the fusion 132 
genes is usually a good proxy for the presence of the fusion. If the aberration 133 
causing the fusion is balanced, detection becomes much more difficult[38]. If there 134 
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are breakpoint `hotspots' across tumours (i.e. the double-stranded breaks occur 135 
within kilobases of each other) then PCR primers can be designed either side of the 136 
break to detect the fusion using fresh or fixed DNA[39]. Otherwise, if the breaks 137 
occur in intermediate size regions, exon/intron capture[5] or long-range PCR[40] is 138 
required, providing that the DNA is of sufficient quality to yield long enough 139 
fragments[41]. Finally, for breaks which are not recurrent, paired-end WGS is the 140 
preferred approach.  141 
 142 
It has, however, been shown that fusions can be detected using targeted sequencing 143 
either using a specific protocol which ligates nuclear proximal sequences for a gene 144 
of interest - TLA[42] or bioinformatically from chimeric reads in existing targeted 145 
sequencing data - BreaKmer[43]. It is also possible to interrogate RNA rather than 146 
DNA to detect fusions - if the breaks across patients result in the fusion of the same 147 
exons, targeted PCR based assays can be designed to pick up the fusion product in 148 
RNA, even from short fragments, with the caveat that the fusion must be expressed 149 
in the cells[44]. If only one of the fusion partners is known, PCR baits for the exons 150 
of the known partner can be paired with random hexamer priming to amplify the 151 
fragment for any fusion partner[45].      152 
 153 
Oncogene amplification - Figure 1b 154 
High-level gene amplification typically arises via focal copy-number change[46]. A 155 
canonical example in the clinic is the amplification of ERBB2 in breast cancer 156 
patients, resulting in HER2 overexpression which can be treated with the antagonist 157 
trastuzumab[47]. Recently, ERBB2 amplification has been demonstrated to occur in 158 
many tumour types, albeit at lower frequency, supporting the potential rational use of 159 
HER2 antagonist therapy[48]. Although, a recent clinical trial of off-label therapy use 160 
based on molecular characterisation showed no widespread benefit suggesting this 161 
strategy may be specific to certain therapies[49]. HER2 status is commonly 162 
assessed using IHC, with ERBB2 amplification interrogated using FISH or CISH if 163 
IHC is uncertain[50]. Recently, it has been shown that sequencing based 164 
technologies such as ddPCR show greater clinical efficacy[51]. In many cases 165 
however, the interrogation of multiple genes simultaneously may improve clinical 166 
decision making (Box 1). 167 
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 168 
Targeted gene panels, exome and WGS based approaches all allow detection of 169 
amplifications across many chromosomal positions simultaneously, with varying 170 
accuracy and sensitivity. Methods for detection generally rely on read depth, 171 
heterozygous germline SNP allele frequencies, or a combination of both[52]. 172 
However, determining the precise number of copies can be difficult, especially for 173 
samples with low tumour cell content[5]. In these cases, a copy-number aberration 174 
will not be detected using low coverage sequencing unless the amplification is in 175 
excess of 6 copies[5]. Conversely, while targeted gene panels generally provide a 176 
read depth necessary for copy-number detection, artefacts such as PCR or 177 
hybridisation efficiency can skew the estimated copy-number. Despite these caveats, 178 
technical and algorithmic developments are yielding promising results, for example, 179 
the ability to sensitively detect AR and CYP17A1 gains in the serum of castrate 180 
resistant prostate cancer patients[53]. 181 
 182 
Enhancer hijacking - Figure 1c 183 
While there are not yet any examples of enhancer hijacking being targeted in the 184 
clinic, this mechanism provides a prototypical example for both the potential of large-185 
scale tumour genomics studies to generate new targeted therapy avenues, and the 186 
associated complexities with functional interpretation. A recent study of whole-187 
genome sequencing data from 137 medulloblastoma samples revealed clusters of 188 
SV breakpoints at 9q34 which correlated with strong upregulation of GFI1B in a 189 
subset of tumours[54]. Further investigation showed these SVs, made up of various 190 
classes, all juxtaposed active enhancers to GFI1B, increasing expression of the 191 
proto-oncogene. While this work reveals a potential therapeutic target for treatment 192 
of a subset of medulloblastomas, routine detection of these cases would currently 193 
require whole-genome sequencing coupled with gene expression profiling - a costly 194 
and labour intensive diagnostic. Until WGS is widely adopted, this class of SV is 195 
likely to remain undetected in a clinical setting.      196 
 197 
Tumour suppressor deletion - Figure 1d 198 
Deletions are the most complex class of SVs to detect and interpretation is two-fold 199 
as confirmed inactivation of both copies is required. There are four common paths to 200 
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tumour suppressor inactivation: 1) a deleterious heterozygous germline mutation 201 
coupled with loss of the functional copy, such as BRCA1 in breast cancer[55]; 2) a 202 
somatic point mutation in one allele, followed by loss of the remaining copy, such as 203 
TP53 in ovarian cancer[14]; 3) epigenetic silencing of one copy followed by loss of 204 
the functional copy, such as MLH1 in colorectal cancer[56]; or 4) homozygous loss of 205 
both copies via two separate deletion events.  206 
 207 
Deletions of protein coding genes causing loss of function are typically diagnosed 208 
using IHC. However, IHC is commonly not applicable owing to lack of validated 209 
clinical antibodies (e.g. detection of NF1 protein) or when the functional impact is a 210 
result of a non-coding change such as the loss of a microRNA with unknown protein 211 
target[57]. To confirm a loss of function with sequencing, two assays may be 212 
required, one to confirm the copy-number change and another to confirm the 213 
secondary hit on the remaining copy[58]. Depending on the distribution of 214 
heterozygous germline SNPs in the region of interest, determining LOH in tissue 215 
samples may require an estimate of the tumour purity (fraction of tumour cells 216 
relative to normal) and ploidy. This can usually only be estimated using genome-217 
wide profiling techniques (array or sequencing based) in combination with 218 
computational algorithms such as ASCAT[59] or ABSOLUTE[60] which can 219 
determine the most likely purity and ploidy state. Given these limitations, the use of 220 
sequencing-based assays for detecting deletions will not be sufficient for 221 
unambiguous detection of loss of function without further advances in technology 222 
and clinical workflow.  223 
 224 
Genomic instability - Figure 1e 225 
Integrating data from multiple SVs using genome-wide profiling can reveal diagnostic 226 
and prognostic information which now offer clinically useful biomarkers [61–63] in 227 
contrast to the current uncertainty about which single SV event is dominant or 228 
actionable (discussed below). Scores for focal complex rearrangements such as the 229 
complex arm aberration index (CAAI) have prognostic power in breast cancer[64] 230 
and have been shown to be robust across larger cohorts of breast and high grade 231 
serous ovarian cancer cases[65]. In gastrointestinal tumours, a Genomic Index (GI) 232 
integrating the number and type of copy-number changes has been linked with 233 
8 
 
prognosis[66], and may be useful for molecularly stratifying intermediate risk disease  234 
[67]. In addition other integrative measures of genomic instability developed from 235 
loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large-scale state 236 
transitions (LST) have been correlated with underlying homologous recombination 237 
deficiency in breast cancer and related sensitivity to platinum-based chemotherapy 238 
[68] and subsequently commercialized. Similar approaches are also in development 239 
for predicting response to PARP inhibitors in high grade serous ovarian cancer 240 
[69,70]. Further validation of these signatures in large cohorts is now required 241 
together with comparison to other signatures that may reflect specific aberrant DNA 242 
damage and repair, similar to the SNV signatures identified using non-matrix 243 
factorization[71]. 244 
 245 
While these approaches use complex rearrangements to compute global measures 246 
of instability, it is not yet possible to accurately resolve complex events to the point 247 
where underlying drivers can be determined. However, by integrating short-read 248 
sequencing data with 10X Genomics synthetic long-read technology and BioNano 249 
Genomics mapping, it may be feasible to resolve these events from the resulting 250 
phased, long-reads[72].  251 
 252 
Technology frontrunners 253 
Balancing cost and sensitivity: shallow whole-genome sequencing 254 
Advances in methods that adjust for GC sequencing bias, along with careful curation 255 
(“black-listing”) of problematic genomic regions has dramatically improved depth of 256 
coverage approaches for genome-wide copy number profiling[73]. It is now possible 257 
to obtain a meaningful genome-wide copy-number profile from sequencing depths as 258 
low as 0.1×, applied to FFPE or frozen samples[73]. If matched germline samples 259 
are processed, it is possible to discern germline from somatic copy-number 260 
alterations. However, even in the absence of matched germline it is still possible to 261 
extract reliable copy-number profiles with clinical utility (see Box 4).   In addition, if 262 
the DNA is of sufficient quality, long-insert paired-end shallow whole-genome 263 
sequencing can be used to obtain both copy-number and balanced rearrangement 264 
information[74]. It is has also been shown that these shallow whole-genome 265 
sequencing (sWGS) techniques can be used to interrogate circulating tumour DNA in 266 
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plasma[75]. These advances pave the way for a cost effective genome-wide profiling 267 
strategy for monitoring copy-number changes in tumours in response to therapy.  268 
 269 
One caveat of these techniques in the cancer setting is that their performance is 270 
tightly coupled to both tumour purity and ploidy of the sample[76]. Furthermore, a 271 
critical feature for monitoring therapy response is the ability to observe and account 272 
for tumour heterogeneity[77]. In the case of copy-number profiling, tumour 273 
heterogeneity can be observed as a mixture of copy-number states which result in a 274 
non-integer copy-number. However, to decide whether a copy-number is non-275 
integer, absolute copy-number changes rather than relative copy-number changes 276 
must be observed. For this, estimates of purity and ploidy are required[59]. In the 277 
absence of deeper WGS, reasonable estimates for these can be obtained via 278 
histopath and FISH/CISH, or bioinformatically inferred[60]. If available, we highlight 279 
in Box 2 that subclonal copy number changes are theoretically detectable with a 280 
sWGS strategy. One cost-effective approach is to couple sWGS with exome seq 281 
facilitating absolute copy-number calling[73]. 282 
 283 
Getting more bang for the buck: advanced bioinformatics 284 
Advances in bioinformatic approaches have boosted our ability to extract useful 285 
information out of relatively low-coverage sequencing experiments. For example, 286 
exome and targeted gene panels that were originally designed to interrogate only 287 
SNVs and INDELs, are now being extended to estimates of copy-number[78,79]. 288 
Furthermore, a perceived defect of exome capture, namely inefficient hybridization 289 
causing “off target” reads, has been transformed into a useful data source for 290 
reconstructing genome-wide copy-number number profiles[80].  291 
 292 
Other improved algorithms also make it possible to go beyond the simple binary 293 
score indicating presence or absence of a given mutation—by using the allele 294 
frequency of a mutation it is possible reconstruct the evolution of a tumour and 295 
determine the fraction of tumour cells that contain the mutation, even for SVs[37,81]. 296 
This may have strong clinical benefits, as detecting actionable mutations that are 297 
present on the trunk of the tumour phylogenetic tree rather than the branches, may 298 
allow selection of therapy that targets the bulk of the tumour cells[77].  299 
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 300 
Some pitfalls 301 
Beyond the technical issues associated with detection, there are other factors which 302 
obscure clinical decision making using SVs: 303 
 304 
More than one driver mutation 305 
In Box 1 we use a hypothetical scenario to illustrate the challenges faced when a 306 
copy-number change is observed across multiple drivers, of which only one is the 307 
true driver. In this case, neither WGS or targeted sequencing can resolve the 308 
dilemma, each with their own shortcomings. The situation becomes worse when 309 
dealing with unstable genomes, where complex rearrangements can result in a list of 310 
putative drivers ranging in the 1000s. The SNV profiling field has faced a similar 311 
challenge, thus many of the methods developed can be adapted to SVs[82].  312 
Approaches that use gene and protein interaction networks to elucidate key driver 313 
pathways hit by multiple mutations, offer a promising technique for narrowing the list 314 
of putative driver events to the point where a targeted therapy can be rationalised 315 
(methods reviewed in detail in [83]). Alternatively, integrative SV analysis (see text 316 
above) may offer treatment choices for some patients. 317 
 318 
To assist in the process of therapy rationalisation, many cancer centres have 319 
appointed panels of experts to decide on the best course of treatment given complex 320 
molecular results[84]. These panels are typically made up of clinicians, scientists, 321 
bioinformaticians and others that collectively decide if the molecular evidence is 322 
sufficient to make a therapeutic intervention. While this pipeline results in a high-level 323 
of care, it is ultimately low-throughput. One way to overcome this is to ensure that 324 
detailed information on the decision making process of these panels is captured so 325 
that areas of redundancy and automation can be identified and throughput improved. 326 
One of the critical areas for achieving this improvement is enhanced annotation of 327 
structural variants and the functional impact (including possible confounders). To 328 
help address this,[85] has proposed the introduction of a clinical targetability index, 329 
which is supported by databases of manually curated druggable mutations including 330 
the incorporation of initiatives such as My Cancer 331 
Genome[https://www.mycancergenome.org], Targeted Cancer 332 
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Care[https://targetedcancercare.massgeneral.org], and Personalized Cancer 333 
Therapy[https://pct.mdanderson.org]. Measures such as these will assist clinicians in 334 
deciding which aberrations to target. 335 
 336 
Tumour heterogeneity 337 
Tumour heterogeneity is another factor that impacts strongly on the clinical 338 
interpretation of mutations. Discussed extensively recently[83,86] tumour 339 
heterogeneity has a profound effect on the choice of sequencing approach for 340 
interrogating SVs in tumours.  While WGS provides a comprehensive view of the 341 
genomic makeup of a tumour, this is limited in absolute depth, revealing only 342 
mutations found in the bulk of tumour cells.  In contrast, targeted sequencing 343 
provides a deeper, narrow view, with the potential benefit of detecting tumour 344 
heterogeneity for single mutations. This may be critical in cancers where 345 
identification of initially, small, resistant populations of cells is paramount. A recent 346 
review by Hiley et al. [77] highlights how modelling tumour heterogeneity and 347 
understanding the life history of a tumour can assist with prioritizing therapeutic 348 
targets. By targeting mutations that arise early in tumour development present in all 349 
cells, the bulk of the tumour will be hit by the treatment. Alternatively, by 350 
characterising cells with different driver mutations, combination therapies can be 351 
designed so that all observed drivers are targeted. Methods for identifying 352 
heterogeneous copy-number aberrations[87] and SVs[37], are likely to have a 353 
significant impact on improved decision making (See Box 3 for an example of how 354 
clonality analysis is currently being used to inform therapy in the clinic). Currently, 355 
though, the majority of these methods are designed to use deep WGS as input and 356 
further technical and algorithmic developments are required for routine assessment 357 
of copy-number heterogeneity using targeted or shallow sequencing strategies. 358 
 359 
Necessary hurdles 360 
A putative sequencing based biomarker must be subjected to rigorous testing of its 361 
analytical validity, clinical validity and clinical utility[88] before widespread adoption in 362 
the clinic. In the context of SVs, this would typically mean proving that the SV can be 363 
accurately and robustly detected (analytical validity); showing that the SV associates 364 
with the clinical outcome of interest, in this case, target gene activity in the tumour 365 
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(clinical validity); and demonstrating that the detection of the SV leads to a targeted 366 
therapy which improves patient outcomes (clinical utility). These are major 367 
challenges with even analytical validation presenting a significant technical and 368 
analytical challenge. For the validation of the copy number calling for the 369 
FoundationOne assay, multiple pools of mixed normal and tumour cell line DNA 370 
were used in ratios of 20-75% tumour content for blinded calling of focal gene 371 
amplification and homozygous deletion across repeat experiments[5]. Establishing 372 
clinical validity for a novel SV will continue to be an expensive and time consuming 373 
process as it relies upon large validation sample sets with orthogonal genomic 374 
characterization with RNA profiling and protein assays. One approach to help 375 
mitigate this may be the use of careful sequencing study designs which are well 376 
powered to inform clinical decision making[2]. Furthermore, careful certification and 377 
accreditation of the bioinformatics pipelines for processing sequencing data is 378 
required to ensure analytical validity[89]. Tools such as Docker, which completely 379 
encapsulate all software needed for the analysis in a virtual machine 380 
(https://www.docker.com/) are improving reproducibility, testing and deployment. SV 381 
specific accreditation of pipelines can draw on the lessons learnt from certification of 382 
SNV pipelines[90], as well as guidelines developed for germline testing[91]. 383 
Promising examples of approaches for somatic detection are emerging such as the 384 
system used by Princess Margaret Cancer Centre for clinical somatic variant 385 
classification[92], however, it is important that SV profiling be integrated in these 386 
systems early in their development as many of the underlying quality control 387 
principles of sequencing use in the clinic apply in both cases.  388 
 389 
To WGS or not to WGS 390 
Since the goal of sequencing a complete genome for $1000 was realised in 2014 391 
[93], there has been continuing debate on whether the time is right to adopt WGS 392 
routinely in the clinic[94]. For reasons outlined above, comprehensive 393 
characterisation of SVs in specific cancers would greatly benefit from routine deep 394 
WGS, however, significant barriers still need to be overcome before this could be 395 
considered feasible. These include a reduction in the high human costs associated 396 
with computational analysis, functional interpretation, and identification of actionable 397 
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drivers. Developing strategies to overcome these challenges is currently uninformed 398 
as there are no studies that have directly assessed the clinical benefit of whole-399 
genome sequencing in cancer although many major cancer centres are starting to 400 
grapple with the significant infrastructure required for clinical WGS. In addition, 401 
several national and regional WGS sequencing efforts are underway that may 402 
mitigate the analysis bottlenecks by economies of scale, albeit by imposition of 403 
pragmatic or restricted bioinformatic reporting to achieve clinically useful turn around 404 
times. In the UK the Genomics England 100,000 Genomes Project has now 405 
sequenced 11,221 genomes from NHS patients being investigated for either rare 406 
inherited disease or somatic sequencing at cancer diagnosis. Similar projects are 407 
ongoing in California, Vancouver and the Netherlands. 408 
 409 
A key technical challenge to overcome in the cancer setting is to be able to process 410 
FFPE material. As far as we are aware, there is no deep WGS published with DNA 411 
isolated from FFPE clinical material. In our hands the sequence yield has been too 412 
low from a single sequence lane of the Illumina X10 to allow genome-wide mutation 413 
analysis. However, the yield was sufficient to perform genome-wide mapping of SVs 414 
(translocation and copy numbers). These challenges can be mitigated by different 415 
bioinformatic methods, however, it is important to acknowledge the overhead 416 
required for the development of bioinformatic approaches which provide clinical 417 
grade mutation calling. In this regard it is particularly instructive to review lessons 418 
learnt from developing SNV calling algorithms. Initial “state-of-the-art” calling 419 
methods developed in academia showed significant discrepancies[95], and it is only 420 
recently we have been able to accurately quantify the performance of the different 421 
approaches via international mutation calling challenges[96]. A significant impact of 422 
the Pan Cancer Analysis of Whole Genomes project (https://dcc.icgc.org/pcawg) has 423 
been the curation of consensus calling strategies using deep WGS from over 2800 424 
tumours, and with this resource we are now in a position to develop and validate 425 
calls that can be deemed robust enough for clinical work. 426 
 427 
While we still have a long way to go before sufficient capability is acquired for 428 
widespread deployment of WGS in the clinic, there are select scenarios where WGS 429 
is already being adopted. Box 3 and Box 4 illustrate two cases where a sWGS 430 
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strategy is replacing aCGH and FISH for assessing copy-number in the clinic. 431 
Another likely candidate for early adoption of WGS in the clinic is genome-wide 432 
characterisation of loss-of-heterozygosity. Knowledge of this, combined with 433 
identification of SNV drivers assists in robust interpretation of putative targets. 434 
 435 
Concluding remarks 436 
Although we expect extensive, ongoing debate on the role of DNA sequencing in the 437 
clinic[97], we see a clear need for cheap and accessible sequencing-based 438 
approaches in the clinic to interrogate SVs and to widen rational therapeutic choices. 439 
These approaches will provide a stronger basis for understanding the genomic 440 
architecture of cancers and should be integrated into large-scale discovery efforts for 441 
clinical biomarkers. In the short term we expect these tools will be used for 442 
orthogonal validation for validated relevant SVs, however over the long term, we 443 
expect modifications of sWGS to become the primary tool for SV detection. Although 444 
deep whole-genome sequencing will provide the most comprehensive approach, 445 
care needs to be taken to develop the correct infrastructure to ensure both test and 446 
analysis costs remain low[98] and practitioners are given sufficient education in 447 
interpretation of sequencing based tests[99]. Until then, a mixed strategy of shallow 448 
WGS and targeted sequencing is likely to be a sufficient framework for diagnosis, 449 
prognosis and tracking treatment resistance.  450 
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 726 
Text Boxes 727 
Box 1 - Oncogene amplification: a clinical dilemma (hypothetical) 728 
Consider a hypothetical situation where a patient presenting with non-small cell lung 729 
cancer has their tumour sequenced using a targeted capture panel for all exons of 730 
EGFR. The results come back negative for SNVs and INDELs, however, the assay 731 
reports a copy-number gain spanning EGFR which can be targeted with a tyrosine 732 
kinase inhibitor[29]. The obvious temptation here is to commence treatment with a 733 
tyrosine kinase inhibitor such as erlotinib. However, what we don’t know in this case, 734 
is that the EGFR gain is a result of a whole chromosome level change, which 735 
happens to incorporate the true tumour driver, MET, also on chromosome 7. MET 736 
amplification is known to confer resistance to erlotinib, but can be targeted with 737 
crizotinib. In this case, only a more comprehensive assay would have allowed us to 738 
identify the true target, although this test would have come at an increased cost. 739 
Furthermore, even if this assay was carried out, we would be faced with another 740 
dilemma: of the two putative targets, which is the true driver gene? Which is likely to 741 
be the most effective treatment? For the capture panel results, there is only one 742 
possible treatment option, which in this case may have resulted in a failed response, 743 
negatively impacting on the perceived efficacy of the treatment and test. Whereas, in 744 
a whole-genome case, uncertainty around which is the true driver is likely to result in 745 
no treatment intervention unless additional testing is carried out to determine the true 746 
driver. Which is the best assay? 747 
 748 
Box 2 - sWGS for monitoring subclonal copy-number changes 749 
The ability to detect subclonal copy-number changes (changes present in a subset of 750 
tumour cells in a sample) is important for measuring intra-tumour heterogeneity and 751 
fluctuations in responsive and resistant clones during therapy. Here we show that, in 752 
theory, sWGS has the power to cheaply and robustly detect subclonal copy-number 753 
changes. By performing power calculations 754 
(https://gmacintyre.shinyapps.io/sWGS_power/), we plot the number of reads 755 
required to detect significant copy-number changes with 80% power as a function of 756 
tumour purity (Figure i). If we assume a modest tumour purity of 54% (the sample 757 
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contains 54% tumour cells, 46% normal) and an average ploidy of 2, we show that 758 
20 million reads is sufficient to detect 1 megabase copy-number changes at 759 
subclonal fractions as low as 20%. This is inline with similar calculations carried out 760 
for arrays[100]. This example highlights the benefit of adopting an affordable sWGS 761 
strategy to measure copy-number changes linked to therapy response. 762 
 763 
 764 
Box 3 - Clonality screening program using copy-number profiling at VUmc 765 
clinic, Amsterdam 766 
The clonal relationship between tumours can be interpreted in an automated fashion 767 
by calculating a likelihood ratio to distinguish tumor pairs[101]. This is used to assist 768 
therapy management of patients with non-small cell lung cancer at the VUmc clinic in 769 
Amsterdam. Patients which present with multiple or secondary tumors, have their 770 
tumours profiled to determine whether they stem from the original primary tumor or 771 
are independent tumors[102]. If tumors are clonal and derived from the primary, the 772 
initial therapy is considered to have been ineffective and treatment is not repeated. 773 
Whereas if the tumor is novel, therapy is continued in the hope that this tumour will 774 
also respond. A low incidence rate (± 1 case/week at VUmc) combined with a 775 
requirement for a fast turnover time (7 days from DNA isolations to diagnosis) 776 
implies high workload, since single cases have to be processed separately. To 777 
reduce per sample cost, a transition from aCGH to sWGS is currently taking place, 778 
however, samples will still have to be run individually given the aforementioned low 779 
incidence rate and required turnover time. To overcome this we are currently using 780 
existing infrastructure that also performs sWGS for non-invasive prenatal testing 781 
(NIPT, [103]). At writing of this review we have finalized the validation phase for 782 
accreditation purposes to transition from arrays to sWGS for the clonality analysis, 783 
where the assay has been run in parallel on both platforms. This transition from 784 
arrays to sWGS will be an enormous time and cost saving measure, whilst adhering 785 
to the same high diagnostic standards required by the accreditation measures 786 
applied in the lab (CCKL accredited: ISO 15189:2007 certificate 111). 787 
 788 
Box 4 - Diagnosis of low grade gliomas warrants genome-wide copy number 789 
profiling 790 
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In low-grade gliomas, 1p and 19q codeletion is currently recommended as a 791 
prognostic indicator for use in the clinic [11]. If present, a watchful waiting approach 792 
is adopted rather than immediate aggressive treatment.  For this diagnosis, whole 793 
arm losses of 1p and 19q are mandatory; however common tests currently in use, 794 
use FISH probes which sample one or few chromosomal locations[21]. Importantly, it 795 
is the loss of whole chromosome arms, not parts, that are the true prognostic 796 
indicators. Moreover, it has been shown that inter-observer variability analysis of 797 
“oligo-dendroglioma” using histo-pathology (only) would be highly reduced by 798 
measuring the clonal 1p/19q co-deletion in these tumors [11,104]. These factors 799 
combined make a strong case for switching to a more comprehensive genome-wide 800 
copy-number profiling strategy[7]. At the time of writing, the VUmc in Amsterdam, 801 
that routinely carries out this diagnostic is opting to run all low-grade gliomas 802 
samples using both sWGS (see Figure ii for an example) in parallel with the current 803 
FISH test and side-by-side (thus same sequence lanes) with the NIPT and clonality 804 
tests outlined in Box 3.  805 
 806 
 807 
808 
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 809 
 810 
Glossary 811 
aCGH: array Comparative Genomic Hybridisation. A DNA microarray used for 812 
determine copy-number, typically genome-wide.  813 
BreaKmer: A bioinformatic algorithm which uses chimeric reads in existing 814 
sequencing data to determine the existence of structural variant breakpoints. 815 
CISH: Chromogenic In Situ Hybridization. A cytogenetic technique where probes 816 
labelled with biotin or digoxigenin are hybridised to specific regions of the genome 817 
and observed under a widefield microscope.  818 
ddPCR: Digital droplet polymerase chain reaction. PCR performed on a single 819 
molecule that has been isolated in a water-oil emulsion droplet.  820 
FFPE: Formalin fixed paraffin embedded. A term used to describe tissue samples 821 
that have been fixed in a formalin solution and embedded in paraffin wax blocks. 822 
FISH: Fluorescent In Situ Hybridisation. A cytogenetic technique where fluorescently 823 
labelled probes are hybridised to specific regions of the genome and observed under 824 
a fluorescent microscope.  825 
IHC: Immunohistochemistry. The detection of antigens from tissue sections using 826 
specific antibodies that bind the antigen with either chromogenic or fluorescent 827 
reporters.  828 
INDEL: Insertion/deletion (somatic). A small stretch of base-pairs, typically 3-10 in 829 
length that is either deleted or inserted in the tumour genome. 830 
MLPA: Multiplex ligation-dependent Probe Amplification. A multiplex PCR assay for 831 
detecting changes in copy-number. 832 
PCR: Polymerase chain reaction. A molecular technique used to amplify DNA.  833 
SNP array: Single nucleotide polymorphism array. A DNA microarray used to call 834 
germline variation that can also be used to determine copy-number. 835 
SNV: Single-nucleotide variant (somatic). A mutation resulting in the change of a 836 
single base-pair in the genome of a tumour cell.  837 
SV: Structural variant (somatic). A double stranded break in the DNA of a tumour cell 838 
resulting in either a balanced rearrangement where no DNA is lost such as an 839 
inversion or translocation, or in an unbalanced rearrangement such as a deletion or 840 
amplification (also known as a copy-number aberration).   841 
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sWGS: Shallow whole-genome sequencing. Short read sequencing of tumour 842 
genomes with limited read depth, typically less than 1x coverage. 843 
TLA: Targeted locus amplification. A technique where regions of interest are 844 
amplified along with their ligated sequence determined via cross linking of physically 845 
proximal sequence.  846 
WGS: Whole-genome sequencing. Short-read sequencing of an entire tumour or 847 
normal genome. Typically 30x coverage. 848 
 849 
 850 
 851 
852 
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 853 
 854 
Figure Legends 855 
 856 
Figure i - Power curves for detecting a copy-number change of. The y-axis is tumour 857 
purity (the fraction of tumour cells in the sample) and the x-axis is number of aligned 858 
reads. Any sample lying above the curve will have sufficient power to detect a copy-859 
number change +1 with a bin size of 500kb. The percentage label next to each curve 860 
represents the percentage of tumour cells containing the copy-number change.   861 
 862 
Figure ii - Chromosomal copy-number profile of a diffuse low grade glioma with a 863 
1p/19q co-deletion generated by sWGS with DNA isolated from FFPE. Co-deletion of 864 
the entire 1p and 19q chromosomal arms are indicative of a watchful waiting 865 
treatment strategy. The y-axis represents normalized log2 sequence read counts per 866 
bin, and the x-axis represents 15 kb bins ordered by genomic position from 867 
chromosomes 1 to 22. 868 
 869 
Figure 1 - A schematic of how different classes of structural variation can result in a 870 
potentially “actionable” genomic change. Alongside each is a summary of the 871 
sequencing and non-sequencing based tools that can be used for detection ordered 872 
from most comprehensive, to least. Where applicable, a prototypical example of a 873 
targetable mutation arising as a result of the class of structural variation is listed, 874 
along with its associated treatment. a) and c) are examples of balanced structural 875 
variants that do not result in any loss or gain of genetic material. In contrast, b) and 876 
d) are examples of unbalanced structural variants, also known as copy-number 877 
aberrations, that involve changes in the amount of genetic material in the nucleus.  878 
The technologies listed that interrogate all of these aberrations in a clinical setting 879 
involve a trade-off between cost, resolution, comprehensiveness, and applicability to 880 
formalin-fixed clinical samples. (Reviewed in [25,84,105].) 881 
